Drug Approval | April 22, 2026
US FDA okays Merck's new once-daily HIV pill
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pharma giant targets new standards of care
Highlights Mirvetuximab-based regimen promise
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The decision is based on the phase 3 DESTINY-Breast11 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
